Trial
NCT03308786
HIV Reservoir Reduction With Interleukin-2
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Case Western Reserve University
Collaborators
—
Condition
HIV Infection
Intervention
Recombinant Interleukin-2
Why stopped
There were 3 instances of adverse events which were discussed with external safety monitoring committee and it was recommended that the study be terminated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-28